Kyverna to Present Data on 50 Patients at EULAR 2024 Symposium

Kyverna Therapeutics, Inc., a biopharmaceutical company dedicated to developing cell therapies for autoimmune disease patients, will host a significant symposium showcasing the latest data from the CAR in KYV-101. This event will be held on June 14, 2024, from 8:15 a.m. to 9:30 a.m. CEST, under the title "Anti-CD19 CAR T-Cell Therapy in Rheumatologic Autoimmune Diseases and Beyond." The symposium will highlight insights from ongoing clinical trials and patient initiatives from experts in rheumatology and neurology.

The data presented will focus on a cohort of 50 patients treated with KYV-101, an autologous, fully human anti-CD19 CAR T-cell immunotherapy, demonstrating its safety profile across various indications. Specifically, a set of 30 patients has undergone over 28-day follow-ups, revealing early efficacy data for autoimmune diseases. Additionally, a 12-month follow-up on the first patient treated for myasthenia gravis will be unveiled.

Kyverna's symposium will feature notable speakers such as Dr. Gerhard Krönke from the University of Erlangen-Nuremberg, Dr. Peter A. Merkel from the University of Pennsylvania, Dr. Richard Furie from Northwell Health, Dr. Roberto Caricchio from the University of Massachusetts, and Dr. James Chung and Peter Maag, Ph.D., from Kyverna Therapeutics.

Later on June 14, a press conference will be hosted with Georg Schett, M.D., vice president of research at Friedrich-Alexander University, and Dr. Peter A. Merkel. Both experts are members of Kyverna’s Scientific Advisory Board.

On June 12, Kyverna will also present two posters focusing on the preclinical development of KYV-201, an allogeneic product candidate, and proteomic markers linked to CAR T therapeutic response in autoimmune diseases. Peter Maag, Ph.D., CEO of Kyverna, emphasized the growing interest in cell therapies for autoimmune diseases, noting that KYV-101 is advancing clinical trials in both rheumatology and neurology.

KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate designed to improve tolerability. Developed by the NIH, it was tested in a 20-patient Phase 1 oncology trial, with results published in Nature Medicine. In the U.S. and Germany, KYV-101 is being evaluated in Phase 1/2 and Phase 2 trials for various autoimmune diseases, including lupus nephritis, systemic sclerosis, and multiple sclerosis. The treatment has been administered to 50 patients across more than 15 centers in Europe and the U.S. so far.

Kyverna’s pipeline also includes next-generation CAR T-cell therapies in both autologous and allogeneic formats, tailored for B cell-driven autoimmune diseases. The company aims to advance these therapies to provide novel treatment options for patients.

Additionally, Kyverna will have an exhibit at EULAR (booth E22-23) for healthcare practitioners and patient advocates interested in learning more about their developments.

Kyverna Therapeutics, Inc., listed on Nasdaq as KYTX, continues to focus on innovative cell therapies for autoimmune diseases. Their lead candidate, KYV-101, is being thoroughly evaluated through various clinical trials, demonstrating the company's commitment to pioneering new treatment paradigms.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!